2025
Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure
Barbano R, Jabbari B, Sadeghi M, Ukah A, Yue E, Ifantides K, Huang N, Swope D. Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure. Toxins 2025, 17: 148. PMID: 40137921, PMCID: PMC11945862, DOI: 10.3390/toxins17030148.Peer-Reviewed Original ResearchConceptsIncidence of dysphagiaCervical dystoniaComorbid conditionsContinuous health plan enrollmentCohort entry dateRate of dysphagiaRetrospective cohort studyPre-existing dysphagiaHealth plan enrollmentRisk factors of dysphagiaFactors of dysphagiaReal-world studyPotential adverse eventsPotential risk factorsPatient-level dataReal-world analysisAdverse eventsCD patientsCohort studyComorbid neurological conditionsLongitudinal patient-level dataCD diagnosisDysphagiaDysphagia riskPatients
2023
Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
Humphrey S, Dover J, Bowsher R, Clancy A, Liu Y, Prawdzik G, Gallagher C. Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines. Aesthetic Surgery Journal 2023, 43: 1189-1193. PMID: 37051886, PMCID: PMC10501746, DOI: 10.1093/asj/sjad101.Peer-Reviewed Original ResearchMeSH KeywordsBotulinum Toxins, Type ADouble-Blind MethodForeheadHumansInjectionsNeuromuscular AgentsNeurotoxinsSkin AgingTreatment OutcomeConceptsClinical responseTreatment cyclesDuration of clinical responseOpen-label safety studyGlabellar line treatmentSingle-dose studyBotulinum toxin type A formulationsComplete treatment failureDuration of actionDouble-blindPlacebo-controlledTreatment failureLine treatmentAnalysis populationClinical efficacyDaxibotulinumtoxinAGlabellar linesWeek 4PatientsImmunogenic potentialAntibody formationClinical practiceBinding antibodiesAntibodiesSafety studiesClinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
Gallagher C, Bowsher R, Clancy A, Dover J, Humphrey S, Liu Y, Prawdzik G. Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials. Toxins 2023, 15: 60. PMID: 36668880, PMCID: PMC9862169, DOI: 10.3390/toxins15010060.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, NeutralizingBotulinum Toxins, Type ADouble-Blind MethodHumansInjectionsMiceNeuromuscular AgentsSkin AgingTreatment OutcomeConceptsBinding antibodiesNeutralizing antibodiesNo subjectImmune-related adverse eventsAnti-drug antibody formationAntibody formationGlabellar line severityRate of antibody formationPhase 3 trialMouse protection assayDaxibotulinumtoxinAAdverse eventsBotulinum toxin type A productsGlabellar linesClinical immunogenicityWeek 4Protection assayLow titersAntibodiesEvaluated subjectsLine studiesTitersSubjectsInjectionPlacebo
2021
Development of Objective Structured Assessment of Technical Skills in facial cosmetic procedures: Botulinum toxin neuromodulator and soft-tissue filler injection
Suozzi KC, Kibbi N, Lee KC, Worley B, Furlan KC, Kang BY, Ibrahim SA, Poon E, Alam M, Group C. Development of Objective Structured Assessment of Technical Skills in facial cosmetic procedures: Botulinum toxin neuromodulator and soft-tissue filler injection. Journal Of The American Academy Of Dermatology 2021, 86: 463-467. PMID: 34499988, DOI: 10.1016/j.jaad.2021.08.063.Peer-Reviewed Original Research
2020
Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population
Torabi SJ, Kasle DA, Savoca EL, Gottschalk CH, Manes RP. Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population. Headache The Journal Of Head And Face Pain 2020, 61: 373-384. PMID: 33337542, DOI: 10.1111/head.14040.Peer-Reviewed Original ResearchConceptsAdvanced practice providersHigh-volume providersMedicare populationTreatment modalitiesMedicare patientsPractice providersSubstantial geographic variationMedicare Provider UtilizationProcedure volumeCPT codesPopular treatmentHigher mean numberNeurologistsCross-sectional dataProvider UtilizationMean numberPhysiciansSubstantial proportionChemodenervationReimbursement trendsTreatmentTotal beneficiariesProvidersTotalTotal numberBotulinum Toxin for the Treatment of Motor and Phonic Tics: A Case Report
Kohli N, Blitzer A. Botulinum Toxin for the Treatment of Motor and Phonic Tics: A Case Report. Annals Of Otology Rhinology & Laryngology 2020, 129: 625-627. PMID: 31906695, DOI: 10.1177/0003489419898211.Peer-Reviewed Original ResearchMeSH KeywordsAdultBotulinum Toxins, Type AFacial MusclesHumansInjections, IntramuscularLaryngeal MusclesMaleNeuromuscular AgentsTourette SyndromeTreatment OutcomeConceptsYale Global Tic Severity ScaleTreatment of motorPhonic ticsCase reportTic Severity ScaleFacial mimetic musculatureOnabotulinum toxinFiberoptic visualizationBotulinum toxinThroat clearingTic disordersSeverity ScaleTic severityObjective decreaseMimetic musculaturePatientsTreatmentLevel VExperienced reductionsMusculatureToxinReportGruntingBoNTSeverity
2018
Botulinum Toxin in Restless Legs Syndrome—A Randomized Double-Blind Placebo-Controlled Crossover Study
Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum Toxin in Restless Legs Syndrome—A Randomized Double-Blind Placebo-Controlled Crossover Study. Toxins 2018, 10: 401. PMID: 30274305, PMCID: PMC6215171, DOI: 10.3390/toxins10100401.Peer-Reviewed Original ResearchConceptsRestless legs syndromePain scoresCrossover studyLegs syndromePlacebo-controlled crossover studyDouble-blind placeboPatient Global ImpressionVisual analog scalePrevious smaller studiesCommon movement disorderQuality of lifeIncobotulinumtoxin APlacebo groupRLS symptomsAnalog scaleGlobal ImpressionOnabotulinumtoxin ALife QuestionnaireTibialis anteriorBotulinum toxinNormal salineMovement disordersRLS scoresSmall studyFemoris muscleBotulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach
Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. Parkinsonism & Related Disorders 2018, 56: 65-69. PMID: 29929813, DOI: 10.1016/j.parkreldis.2018.06.019.Peer-Reviewed Original ResearchConceptsHand weaknessEssential hand tremorDouble-blind placebo-controlled studyEssential tremorAdministration of onabotulinumtoxinASevere hand weaknessPlacebo-controlled studyClinical rating scoresHand tremorRating scoresParkinson's disease tremorIncobotulinumtoxinA injectionsCrossover trialPatients' perceptionsBotulinum toxinTreatment efficacyClinical practiceHand strengthForearm musclesTremor severityClinical scalesTremorWeeksTreatmentInjectionBotulinum toxin treatment of pain syndromes –an evidence based review
Safarpour Y, Jabbari B. Botulinum toxin treatment of pain syndromes –an evidence based review. Toxicon 2018, 147: 120-128. PMID: 29409817, DOI: 10.1016/j.toxicon.2018.01.017.Peer-Reviewed Original ResearchConceptsLevel B evidencePain syndromeLevel of evidencePelvic painB evidenceMale pelvic pain syndromeChronic low back painTraumatic spinal cord injuryEfficacy of BoNTFemale pelvic painMale pelvic painVastus lateralis imbalanceMyofascial pain syndromePelvic pain syndromePost-herpetic neuralgiaAnterior knee painBotulinum toxin treatmentPainful knee osteoarthritisPost-operative painDifferent pain syndromesLow back painSpinal cord injuryCarpal tunnel syndromeTotal knee arthroplastyRole of BoNTPharmacological considerations in the elderly
Akhtar S. Pharmacological considerations in the elderly. Current Opinion In Anaesthesiology 2018, 31: 11-18. PMID: 29189287, DOI: 10.1097/aco.0000000000000544.Peer-Reviewed Original ResearchConceptsAnesthetic drugsNeurophysiological changesPoor perioperative outcomesCurrent practice patternsLarge database studiesDepth of anesthesiaIntraoperative hypotensionPerioperative outcomesElderly patientsAnesthetic medicationsDose adjustmentCNS depressionGeriatric patientsPractice patternsDrug managementPharmacologic studiesReceptor levelsPharmacological considerationsCurrent recommendationsDatabase studyElderly populationFunctional connectivityAnesthetic dosingHypotensionDrugs
2017
Progress on Botulinum Toxin Type A-Induced Pain Relief in the Field of Plastics
Lu X, Chen G, Ren P, Yang Y, Fan F. Progress on Botulinum Toxin Type A-Induced Pain Relief in the Field of Plastics. Journal Of Craniofacial Surgery 2017, 28: 2045-2052. PMID: 28938326, DOI: 10.1097/scs.0000000000003981.Peer-Reviewed Original ResearchMeSH KeywordsBotulinum Toxins, Type AHumansIntraoperative CareNeuromuscular AgentsPain ManagementPain, PostoperativePlastic Surgery ProceduresConceptsBotulinum toxin type AToxin type APain alleviationBotulinum Toxin Type A InjectionsBTX-A injectionMain surgical procedureMajor adverse effectsFavorable side effectType AWeb of ScienceAnalgesic effectivenessInflammatory painNeuropathic painPain reliefPostoperative painA injectionAnalgesic mechanismsNociceptive painRetrospective cohortPostoperative rehabilitationPatient seriesClinical trialsInclusion criteriaSurgical proceduresPainSystemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline.
Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S. Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Annals Of Internal Medicine 2017, 166: 480-492. PMID: 28192790, DOI: 10.7326/m16-2458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic low back painAcute low back painLow back painSystemic pharmacologic therapyBack painPain reliefPharmacologic therapySystemic medicationsAmerican CollegeSystematic reviewPhysicians Clinical Practice GuidelineRadicular low back painShort-term pain reliefNonsteroidal anti-inflammatory drugsSecond verified accuracyCochrane Central RegisterClinical practice guidelinesAnti-inflammatory drugsSkeletal muscle relaxantsShort-term trialsEnglish-language studiesModest effectSystemic corticosteroidsAntiseizure medicationsCentral RegisterIncobotulinumtoxinA Injection for Temporomandibular Joint Disorder
Patel AA, Lerner MZ, Blitzer A. IncobotulinumtoxinA Injection for Temporomandibular Joint Disorder. Annals Of Otology Rhinology & Laryngology 2017, 126: 328-333. PMID: 28290229, DOI: 10.1177/0003489417693013.Peer-Reviewed Original ResearchConceptsTemporomandibular disordersMuscles of masticationPain scoresTemporomandibular jointSaline injectionMuscle tenderness scoresPreinjection pain scoreAverage pain scorePain medication usageTemporomandibular joint disordersGroup one monthIncobotulinumtoxinA groupsIncobotulinumtoxinA injectionsPain medicationExact pathophysiologyPain scaleSignificant painMedication usageAssociated symptomsJoint disordersMasticatory musclesPainPatientsConventional treatmentMuscle disorders
2016
Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia
Lerner MZ, Lerner BA, Patel AA, Blitzer A. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia. The Laryngoscope 2016, 127: 1131-1134. PMID: 27633917, DOI: 10.1002/lary.26265.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOnabotulinum toxinChart reviewFemale groupOnabotulinum Toxin A InjectionsRetrospective chart reviewBotulinum toxin injectionSenior author's databaseAbductor spasmodic dysphoniaIndependent sample twoA injectionAverage followSymptom controlOromandibular dystoniaToxin injectionFemale patientsRetrospective reviewAlternate diagnosisBotulinum toxinAntibody formationFemale genderPossible inverse relationshipInclusion criteriaThyroarytenoid muscle
2015
Male Aesthetics: A Review of Facial Anatomy and Pertinent Clinical Implications.
Farhadian JA, Bloom BS, Brauer JA. Male Aesthetics: A Review of Facial Anatomy and Pertinent Clinical Implications. Journal Of Drugs In Dermatology 2015, 14: 1029-34. PMID: 26355624.Peer-Reviewed Original ResearchMeSH KeywordsBotulinum Toxins, Type ACosmetic TechniquesDermal FillersDermatologyEstheticsFaceFacial MusclesHumansMaleNeuromuscular AgentsSkin AgingConceptsCosmetic proceduresBlood vessel densityAesthetic proceduresPertinent clinical implicationsInvasive cosmetic proceduresMale patientsNumber of menPatient dissatisfactionMuscle massVessel densitySubcutaneous tissueClinical implicationsImproper techniqueCosmetic dermatologyFacial anatomyMenDermatologyFacial proportionsAnatomyFemalesTreatment parametersPatients
2014
Hemifacial Spasm and Neurovascular Compression
Lu AY, Yeung JT, Gerrard JL, Michaelides EM, Sekula RF, Bulsara KR. Hemifacial Spasm and Neurovascular Compression. The Scientific World JOURNAL 2014, 2014: 349319. PMID: 25405219, PMCID: PMC4227371, DOI: 10.1155/2014/349319.Peer-Reviewed Original ResearchConceptsHemifacial spasmMicrovascular decompressionMagnetic resonance imagingSymptomatic reliefFacial nerveNerve root entry zonePrimary hemifacial spasmSecondary hemifacial spasmBotulinum neurotoxin injectionStandard medical managementTreatment of choiceFacial nerve rootRoot entry zoneIpsilateral facial nerveFacial nerve damageFacial movement disordersHFS patientsNerve damageVascular compressionCurative treatmentMedical managementNerve rootsNeurovascular compressionSurgical interventionClinical examination
2012
Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study
Rodriguez L, Rosen R, Manfredi M, Nurko S. Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study. Gastrointestinal Endoscopy 2012, 75: 302-309. PMID: 22248598, PMCID: PMC3260460, DOI: 10.1016/j.gie.2011.09.042.Peer-Reviewed Original ResearchConceptsOpen-label studyBotulinum toxin APredictive factorsToxin ASingle tertiary care centerLong-term clinical outcomesRefractory gastroparesis symptomsSymptoms of gastroparesisPlacebo-controlled trialTertiary care centerManagement of childrenSingle case reportsTreatment of childrenGastroparesis refractoryGastroparesis symptomsIntrapyloric injectionReported exacerbationsSpastic disordersClinical improvementMedian durationOlder patientsBotulinum injectionMale patientsMedical therapyRetrospective review
2011
Treatment of Refractory Pain with Botulinum Toxins—An Evidence-Based Review
Jabbari B, Machado D. Treatment of Refractory Pain with Botulinum Toxins—An Evidence-Based Review. Pain Medicine 2011, 12: 1594-1606. PMID: 21958302, DOI: 10.1111/j.1526-4637.2011.01245.x.Peer-Reviewed Original ResearchConceptsPost-operative painRefractory painBotulinum toxinChronic low back painChronic lateral epicondylitisClass II articlesLevel B evidenceLevel C evidencePost-traumatic neuralgiaVastus lateralis imbalanceMyofascial pain syndromePlacebo-controlled studyPost-herpetic neuralgiaAnterior knee painPainful knee osteoarthritisChronic daily headacheLow back painTotal knee arthroplastyEvidence-based reviewEvidence-based dataSphincter spasmKnee painPain syndromePelvic painPiriformis syndrome
2009
Botulinum Neurotoxin-A for Treatment of Refractory Neck Pain: A Randomized, Double-Blind Study
Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B. Botulinum Neurotoxin-A for Treatment of Refractory Neck Pain: A Randomized, Double-Blind Study. Pain Medicine 2009, 10: 1012-1017. PMID: 19594841, DOI: 10.1111/j.1526-4637.2009.00658.x.Peer-Reviewed Original ResearchConceptsVisual analog scaleRefractory neck painNeck painExcellent respondersPrimary outcomeMean visual analog scaleAdministration of BoNTEfficacy of BoNTUnits of BoNTChronic neck painPlacebo-controlled studyDouble-blind studyImprovement of ADLBotulinum neurotoxinPlacebo groupAnalgesic effectBotox groupFrequency questionnaireSecondary outcomesPain intensityPain localizationPain QuestionnaireAnalog scaleBlinded studyAnimal studies
2008
Botulinum toxin for the treatment of chronic constipation in children with internal anal sphincter dysfunction
Irani K, Rodriguez L, Doody DP, Goldstein AM. Botulinum toxin for the treatment of chronic constipation in children with internal anal sphincter dysfunction. Pediatric Surgery International 2008, 24: 779-783. PMID: 18443801, DOI: 10.1007/s00383-008-2171-3.Peer-Reviewed Original ResearchConceptsInternal anal sphincter dysfunctionAnal sphincter dysfunctionIntrasphincteric injectionSphincter dysfunctionIntractable constipationPediatric patientsBotulinum toxinIAS dysfunctionAbnormal anorectal manometryRectoanal inhibitory reflexTreatment of constipationDuration of effectChronic constipationPostoperative incontinenceRefractory constipationInhibitory reflexAnorectal manometryResting pressureRetrospective reviewBotox injectionHirschsprung's diseaseConstipationEffective treatmentPatientsDysfunction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply